Definium Therapeutics, Inc. (DFTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 11, 2026, specifically the results of the Company's 2026 Annual General and Special Meeting of Shareholders. Definium Therapeutics, Inc. is an emerging growth company incorporated in British Columbia with its principal executive offices in New York, New York.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Shareholders voted on three proposals at the Annual Meeting. As of the record date (April 15, 2026), 109,066,783 Common Shares were outstanding. Approximately 72% of shares entitled to vote were present or represented.
- Proposal 1: Election of Directors - All seven nominees were elected to serve until the 2027 Annual Meeting.
- Robert Barrow: 62,881,122 votes for
- Dr. Suzanne Bruhn: 62,503,873 votes for
- Dr. Roger Crystal: 60,056,178 votes for
- David Gryska: 62,760,423 votes for
- Andreas Krebs: 62,395,043 votes for
- Carol A. Vallone: 62,623,945 votes for
- Roger Adsett: 62,931,294 votes for
- Proposal 2: Appointment of Auditor - Shareholders approved the appointment of KPMG LLP as the independent registered public accounting firm.
- Votes For: 78,579,054
- Votes Withheld: 94,538
- Proposal 3: Approval of Equity Plan Amendment - Shareholders approved an amendment to the 2025 Equity Incentive Plan to increase the number of Common Shares available for issuance by 5,000,000.
- Votes For: 58,149,028
- Votes Against: 4,708,102
- Votes Abstain: 197,368
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks. The Equity Plan Amendment became effective immediately upon shareholder approval. Detailed terms of the amendment are referenced in the Definitive Proxy Statement filed on April 27, 2026, and the full text is attached as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the dilution impact of the newly authorized 5,000,000 shares under the amended 2025 Equity Incentive Plan.
- Review the full text of Exhibit 10.1 for specific terms regarding vesting, exercise prices, and eligibility for the equity plan.
- Confirm the tenure of the newly elected Board of Directors, which extends until the 2027 Annual Meeting.
- Note that KPMG LLP has been reappointed as the independent auditor through the 2027 Annual Meeting.